Stocks · News reference
The health care sector's oversold stocks present buying opportunities for undervalued companies. RSI compares stock strength on up and down days, with an RSI below 30 considered oversold.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Seven sectors are higher and four are lower in Friday’s regular session, with growth sectors holding the top three positions. The leaders are separated rather than clustered, with no single gap clearly standing apart from the other breaks across the table.
The Ozempic market is projected to grow from USD 30.04 billion in 2026 to USD 113.95 billion by 2032, with a CAGR of 24.89%. Growth is driven by expanding diabetes treatment demand, broader metabolic health applications, and increasing adoption of GLP-1 therapies. North America leads the market, while Asia-Pacific emerges as a significant growth region. Key challenges include treatment affordability, reimbursement restrictions, and supply-chain requirements.
Inogen, Inc. announced its third-quarter 2026 financial results, the appointment of Andy Reding as CEO, and the sale of its U.S. oxygen rental business as part of a strategic restructuring.
Eli Lilly and Company has reached an agreement with Hims & Hers to provide patients with direct access to its FDA-approved obesity medications, Zepbound and Foundayo, through the Hims & Hers platform.
Inogen reported Q3 2026 results showing mixed performance with U.S. sales growth of 3.8% driven by new products, but international sales declined 9% due to European customer softness. The company divested its U.S. oxygen rental business for $24.8 million and announced a $20 million cost-reduction program to accelerate profitability. New CEO Andrew Reding outlined plans to streamline operations and expand into adjacent respiratory markets with Aurora and Voxi products. Full-year revenue guidance is $298-301 million with adjusted net loss of $7-8 million.
Law firm Ademi LLP is investigating potential securities fraud claims against Strategic Education (STRA), MNTN, and Veracyte (VCYT). STRA's stock has declined over 20% amid inaccurate statements regarding its Australian business operations, while VCYT has experienced a stock decline exceeding 50%. The firm is seeking affected shareholders to discuss their rights.